Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...

Shares in Acceleron have been grown by the third in the last month, and closed on Friday at almost $168, not far off its 52-week high of $174. Image Phil Taylor ...

Merck agreed to buy Acceleron Pharma Thursday in a deal that values the rare drug specialists at around $11.5 billion. Merck will pay $180 per share for Cambridge, Massachusetts-based Acceleron ...

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.

We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck ...

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

At the time of its Acceleron buyout, the company projected Winrevair, also known as sotatercept, would compete in a PAH drug ...

The company acquired Winrevair, also known by the generic name sotatercept, through an $11.5 billion acquisition of the ...

The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II ...

Italian pharma Chiesi is betting almost $500 million on Gossamer Bio's pulmonary arterial hypertension (PAH) candidate.  | ...

It also comes just a day after Merck agreed to buy Acceleron Pharma for $11.5 billion. In other words, it’s been a busy week for the company. Can the stock continue to push higher? Shares of ...

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming ...